english.prescrire.org > Prescrire International > N°254 - December 2023

n°254

December 2023

Issue Contents
Editorial

Free  Patient characteristics

p.283

Marketing Authorisations


Nirsevimab (Beyfortus°) to prevent RSV infection in infants

p.285-287

Evinacumab (Evkeeza°) in homozygous familial hypercholesterolaemia

p.288-290

Lorlatinib (Lorviqua°) as first-line treatment for certain lung cancers

p.290

Pembrolizumab (Keytruda°) in cervical cancer that has metastasised or after treatment failure

p.291

Pembrolizumab (Keytruda°) after resection of melanoma at high risk of recurrence, and in certain adolescents

p.292-293

Upadacitinib (Rinvoq°) in ulcerative colitis

p.293

Trastuzumab deruxtecan (Enhertu°) in metastatic HER2-positive breast cancer, after one prior line of anti-HER2 therapy

p.294

Burosumab (Crysvita°) in tumour-induced osteomalacia

p.295-296

Dimethyl fumarate (Tecfidera°) in multiple sclerosis in adolescents

p.296

Ruxolitinib cream (Opzelura°) in vitiligo

p.297-298

Trastuzumab deruxtecan (Enhertu°) in metastatic HER2-positive breast cancer, after several treatment failures

p.298

Adverse Effects


Ustekinumab (Stelara°): no live vaccines before 6 months of age for infants who have been exposed in utero

p.299

Zonisamide: as dangerous as topiramate 
during pregnancy?

p.300-301

Editors' opinion. Beyond the SmPC

p.301

Amiodarone: interstitial lung disease

p.302

Antiandro­gens: cognitive disorders

p.302

Clindamycin: mucosal burns

p.303

­Common stem: -tadine

p.303

Outlook


Negative post-marketing trials: often ignored

p.304-305

Free  France's health technology assessment body: pushed to lower the bar!

p.305

Free  Drugs to avoid: an analysis of Australia's pharmaceuticals market

p.306

Free  Proposed multi-stakeholder platform to improve clinical trials in the European Union

p.306-307

Post-marketing studies following conditional authorisation: often lacking

p.307

Masthead


Free  Masthead

p.282

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe